Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budesonide/formoterol - Teva Pharmaceutical Industries

Next Previous
Drug Profile

Budesonide/formoterol - Teva Pharmaceutical Industries

Alternative Names: BF Spiromax®; BiResp Spiromax; Budesonide/formoterol - Teva; Budesonide/formoterol fumarate dihydrate Spiromax®; DuoResp Spiromax; Formoterol/budesonide - Teva; Vylaer Spiromax

Latest Information Update: 24 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 12 Sep 2017 Launched for Asthma (In adults) and Chronic obstructive pulmonary disease (In adults) in South Korea, Israel, Russia (Inhalation) before September 2017
  • 12 Sep 2017 Launched for Asthma (In adults) and Chronic obstructive pulmonary disease (In adults) in Slovenia, Netherlands, Latvia, Italy, France, Croatia, Bulgaria (Inhalation) before September 2017
  • 31 Dec 2014 Launched for Asthma (In adults) in Spain (Inhalation)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top